A1 Over the past five years, AstraZeneca has evolved from a newcomer to a regular at the CIIE, and we have experienced the strong spillover effects of the event. Participating allows us to summarize our phased results in China and open a new chapter of cooperation. At this year's CIIE, AstraZeneca once again set up one of the largest booths in the medical devices and healthcare section to demonstrate our growth in essential therapeutic areas and introduce high-quality innovative products and holistic disease management solutions.

A2 At the CIIE, both this year and in past years, we always hear a "global chorus". It is a place where multinational enterprises can expand their circle of friends and build an ecosystem. Smaller enterprises can also embed themselves in global value chains for new development opportunities. The CIIE has brought huge benefits for these enterprises, whose growths are key indicators of global economic recovery.

The CIIE is a positive signal that China is giving itself and its trading partners in the international community greater confidence, which is crucial in times of economic downturn.

A3 The spillover effect of the CIIE has been amplified, offering opportunities for foreign companies to deeply explore the Chinese market and share its development dividends. More and more foreign exhibitors have planted roots in China, with more exhibits turning into commodities and exhibitors turning into investors.

As a multinational pharmaceutical company, AstraZeneca is one of the beneficiaries of China's growth and opening-up. We will respond to the call for openness and cooperation, and leverage the increasingly enhanced business environment in China to innovate with our partners and benefit patients both in China and around the world.

A4 We believe that China's healthcare industry is still at a stage of fast growth and boasts great opportunities, though not without challenges. In recent years, as the Chinese government and the public attach greater importance to health with economic development, a lot of supportive policies and clearer guidance and regulations have been introduced. High-quality development is one of the priorities set for China's healthcare industry. In that respect, AstraZeneca sees great opportunity in accelerating innovation through cooperation.

A5 Over the past 40 years, China has successfully pursued promoting development through reform and opening-up, staging sustained long-term high-speed economic growth. We are confident in the Chinese market and will continue to share China's development opportunities through expanding operations in the country and working with China to drive the world economy forward.